Does Bictegravir Sodium Emtricitabine And Tenofovir Alafenamide F Interact with Acyclovir?
CDI records a moderate classification for Bictegravir Sodium Emtricitabine And Tenofovir Alafenamide F and Acyclovir. The stored summary is: Coadministration may increase concentrations of acyclovir and renally eliminated drugs, increasing risk of adverse reactions. The mechanism involves competition for active tubular secretion in kidneys. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Bictegravir Sodium Emtricitabine And Tenofovir Alafenamide F Class
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Acyclovir Class
- Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Competition for active tubular secretion in kidneys
What To Tell Your Doctor or Pharmacist
If you are taking Bictegravir Sodium Emtricitabine And Tenofovir Alafenamide F and your doctor is considering prescribing Acyclovir (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider